Prospect Biosystems is a technology-driven proteomics company with a broad-range biomarker discovery capability and instrumentation platform,

• providing rapid biology-based fractionation of complex tissue and cell samples,
• leading to accelerated pharmaceutical discovery, development and commercialization.

Prospect’s Edge^TM (enhanced density gradient extraction) technology is a breakthrough enabling separation technology allowing scientists involved in:

• Analytical Proteomics to significantly enrich low-abundance proteins from their crude cell or tissue extracts;
• Biomarker Discovery to rapidly characterize differences between diseased and healthy tissue;
• Clinical Diagnostics to easily identify and evaluate predictive, diagnostic and prognostic disease biomarkers;
• Surgical Pathology to facilitate outcome prediction through the use of tissue biomarkers, and;
• Clinical Trials to accelerate and improve outcome prediction through the use of surrogate biomarkers.